Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors.
The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Jennifer Buell |
Contact Details
Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States | |
| Phone | 212 994 8250 |
| Website | minktherapeutics.com |
Stock Details
| Ticker Symbol | INKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001840229 |
| CUSIP Number | 603693102 |
| ISIN Number | US6036931029 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer S. Buell Ph.D. | President, Chief Executive Officer and Director |
| Dr. Garo H. Armen Ph.D. | Executive Chairman |
| Christine M. Klaskin | Treasurer and Principal Financial and Accounting Officer |
| Eleni Chantzoura Ph.D. | Director and Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Dec 20, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 6, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |